Breaking News Instant updates and real-time market news.

AHAC

Alpha Healthcare Acquisition

$10.60 /

+0.16 (+1.53%)

07:26
02/17/21
02/17
07:26
02/17/21
07:26

Humacyte going public via merger with Alpha Healthcare Acquisition

Alpha Healthcare Acquisition announced execution of definitive business combination agreement along with a fully committed PIPE financing agreement with Humacyte, a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Upon closing of the transaction, AHAC will be renamed Humacyte, and will be led by Laura Niklason, M.D., Ph.D., CEO of Humacyte. The Combined Company's common stock is expected to be listed on the Nasdaq Capital Market under the ticker symbol "HUMA." A group of leading investors has committed to participate in a common stock PIPE of approximately $175M at $10.00 per share that will close simultaneously with the business combination. The Combined Company will also receive up to $100 million held in AHAC's trust account at closing of the transaction, subject to any redemptions by existing AHAC shareholders. Additionally, existing Humacyte investors will be subject to a 12-month lockup with 50% eligible for sale after 6 months if the 20-day VWAP over any 30-day period equals or exceeds $15.00. Humacyte has assembled a seasoned team of 130 employees, consisting of scientists, clinical, manufacturing, regulatory and commercial experts. Following the closing of the transaction, Dr. Niklason and Mr. Shukla will be joined by certain board members of Humacyte to form the Combined Company's board of directors. Under the terms of the proposed transaction, Humacyte's shareholders will receive an aggregate of 80 million shares of AHAC's Class A common stock in exchange for their existing Humacyte shares, as contemplated by the terms of the business combination agreement. Current shareholders of Humacyte will exchange their shares of Humacyte for Class A Shares on a one for one basis. In addition, Humacyte's shareholders may receive an additional 7,500,000 Class A Shares if the 20-day VWAP of the Class A Shares over any 30-day period equals or exceeds $15.00 and an additional 7,500,000 Class A Shares if the 20-day VWAP of the Class A Shares over any 30-day period equals or exceeds $20.00. In addition to the $100 million held in AHAC's trust account, an additional group of top-tier healthcare investors has committed to participate in the transaction through a common stock PIPE of $175 million at $10.00 per share. Assuming that no AHAC shareholders elect to redeem their shares, it is estimated that the current shareholders of Humacyte will own approximately 73% of the issued and outstanding shares in the Combined Company at closing. The Combined Company is expected to receive gross proceeds of approximately $255 million at the closing of the transaction assuming no redemptions. The transaction is expected to close in the second quarter of 2021. The transaction has been approved by each of AHAC's and Humacyte's Board of Directors. The transaction is subject to the approval of AHAC and Humacyte shareholders and other customary conditions and is expected to close in the second quarter of 2021.

TODAY'S FREE FLY STORIES

Initiation
Sun Country Airlines initiated with a Buy at Goldman Sachs » 21:09
04/11/21
04/11
21:09
04/11/21
21:09
SNCY

Sun Country Airlines

$38.18 /

-0.08 (-0.21%)

Goldman Sachs analyst…

Goldman Sachs analyst Catherine O'Brien initiated coverage of Sun Country Airlines with a Buy rating and $45 price target, implying 18% upside potential from current levels. As an ultra-low cost carrier focused on serving primarily domestic, leisure passengers, Sun Country is well positioned to the "growing recovery" in air travel demand, O'Brien tells investors in a research note. U.S. demand has seen a material improvement in recent weeks, with the 7-day moving average down 38% versus 2019 on April 8 from down 56% at the end of February, almost exclusively driven by leisure demand, says the analyst. O'Brien believes the stock's valuation "remains supportive" despite the 59% increase in shares since the pricing of the initial public offering.

ShowHide Related Items >><<
  • 17
    Mar
SNCY Sun Country Airlines
$38.18 /

-0.08 (-0.21%)

SNCY Sun Country Airlines
$38.18 /

-0.08 (-0.21%)

Hot Stocks
Hill-Rom reconfirms position that BardyDx deal closing conditions not met » 20:54
04/11/21
04/11
20:54
04/11/21
20:54
HRC

Hill-Rom

$112.89 /

+1.6 (+1.44%)

Hillrom previously…

Hillrom previously announced its intent to acquire Bardy Diagnostics. On April 10, the Medicare Administrative Contractor, or MAC, Novitas Solutions, published updated reimbursement rates applicable to the Current Procedural Terminology, or CPT, codes 93241, 93243, 93245 and 93247 for the extended Holter cardiac monitoring category applicable to all of BardyDx's products and services. The original Novitas rate decision was published on January 29, 2021. Following the updated Novitas rate decision, Hillrom reconfirms its position that a "Company Material Adverse Effect" has occurred under the acquisition agreement with BardyDx, and therefore closing conditions have not been satisfied. "Hillrom will not comment further due to current litigation with BardyDx, which is pending in the Delaware Court of Chancery with trial scheduled to begin May 5, 2021. Hillrom remains committed to creating long-term shareholder value, and as previously disclosed will host its fiscal second quarter 2021 earnings conference call and webcast on Friday, April 30," the company stated.

ShowHide Related Items >><<
HRC Hill-Rom
$112.89 /

+1.6 (+1.44%)

HRC Hill-Rom
$112.89 /

+1.6 (+1.44%)

02/08/21 Baird
Hill-Rom price target raised to $115 from $105 at Baird
01/25/21 Morgan Stanley
iRhythm price target raised to $288 from $227 at Morgan Stanley
11/04/20
Fly Intel: Top five analyst downgrades
11/04/20
Hill-Rom cut to Hold at Needham, expecting 'lost year' in FY21
HRC Hill-Rom
$112.89 /

+1.6 (+1.44%)

Hot Stocks
Fly Intel: Top five weekend stock stories » 20:05
04/11/21
04/11
20:05
04/11/21
20:05
MSFT

Microsoft

$255.73 /

+2.37 (+0.94%)

, NUAN

Nuance

$45.59 /

+0.38 (+0.84%)

, DSRLF

DiaSorin SpA

$165.82 /

+0.8151 (+0.49%)

, LMNX

Luminex

$32.92 /

+0.64 (+1.98%)

, AFRM

Affirm

$70.60 /

+0.81 (+1.16%)

, T

AT&T

$30.04 /

+0.04 (+0.13%)

, IIVI

II-VI

$76.26 /

+0.04 (+0.05%)

, GS

Goldman Sachs

$330.85 /

-0.13 (-0.04%)

, CCL

Carnival

$29.30 /

+0.73 (+2.56%)

, NCLH

Norwegian Cruise Line

$30.53 /

-0.08 (-0.26%)

, RCL

Royal Caribbean

$89.86 /

+0.08 (+0.09%)

, CS

Credit Suisse

$10.64 /

-0.305 (-2.79%)

Catch up on the…

Catch up on the weekend's top five stories with this list compiled by The Fly: 1. Microsoft (MSFT) is in advanced talks to buy Nuance Communications (NUAN) in a deal with an equity value of about $16B, or about $56 per share, reported Bloomberg's Liana Baker, Kiel Porter, and Dina Bass, citing people familiar with the matter. Microsoft and Nuance have collaborated since 2019, noted the report, which added that an agreement could be announced as soon as this week. 2. DiaSorin SpA (DSRLF) announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex (LMNX) for a price of $37 per share in an all-cash transaction. This corresponds to a total equity value of approximately $1.8B on a fully diluted basis and an enterprise value of approximately $1.8B. Following the acquisition, the combined entity will have combined 2020 revenues of approximately EUR 1.25B, adjusted EBITDA of approximately EUR 472M, and positive Net Financial Position of approximately EUR 335M. The transaction is expected to close within the third quarter of 2021 and is subject to Luminex shareholder approval and to other customary closing conditions, including the satisfaction of antitrust and CFIUS regulatory requirements. The transaction will be immediately accretive to DiaSorin's earnings per share following closing of the transaction and will generate an attractive return on invested capital profile. The combination is also anticipated to result in cost synergies of approximately $55M within 3 years after closing. 3. The next few months should be boom times for retailers as stimulus checks pump up the economy, but consumers aren't shopping the way they used to as they are souring on credit, and they are increasingly likely to shop online with a digital wallet rather than pull out cash in a store, Daren Fonda wrote in this week's edition of Barron's. The trends are fueling the "buy now, pay later," and they could lift the shares of Affirm Holdings (AFRM), added the author. 4. Legendary and AT&T (T) subsidiary Warner Bros.' "Godzilla vs. Kong" stayed number 1 in its second outing with an estimated $13.4M from 3,084 locations for a domestic cume of $69.5M and a global total of about $360M. The movie is expected to pass up "Tenet" at $365M worldwide sometime this week to rank as the top-grossing during this pandemic. 5. II-VI (IIVI) and Goldman Sachs (GS) saw positive mentions in this week's edition of Barron's, while Carnival (CCL), Norwegian Cruise Line Holdings (NCLH), Royal Caribbean Group (RCL), and Credit Suisse (CS) were mentioned cautiously.

ShowHide Related Items >><<
T AT&T
$30.04 /

+0.04 (+0.13%)

RCL Royal Caribbean
$89.86 /

+0.08 (+0.09%)

NUAN Nuance
$45.59 /

+0.38 (+0.84%)

NCLH Norwegian Cruise Line
$30.53 /

-0.08 (-0.26%)

MSFT Microsoft
$255.73 /

+2.37 (+0.94%)

LMNX Luminex
$32.92 /

+0.64 (+1.98%)

IIVI II-VI
$76.26 /

+0.04 (+0.05%)

GS Goldman Sachs
$330.85 /

-0.13 (-0.04%)

DSRLF DiaSorin SpA
$165.82 /

+0.8151 (+0.49%)

CS Credit Suisse
$10.64 /

-0.305 (-2.79%)

CCL Carnival
$29.30 /

+0.73 (+2.56%)

AFRM Affirm
$70.60 /

+0.81 (+1.16%)

MSFT Microsoft
$255.73 /

+2.37 (+0.94%)

04/09/21 BTIG
Okta upgraded to Buy from Neutral at BTIG
04/08/21 Morgan Stanley
CIO survey provides strong data points for Microsoft, says Morgan Stanley
04/05/21
Fly Intel: Top five analyst initiations
04/05/21 Credit Suisse
Microsoft assumed with an Outperform at Credit Suisse
NUAN Nuance
$45.59 /

+0.38 (+0.84%)

03/10/21 Wedbush
Nuance added to Best Ideas List at Wedbush
03/08/21 Morgan Stanley
Software industry rating raised to Attractive from In-Line at Morgan Stanley
02/09/21 Craig-Hallum
Nuance price target raised to $58 from $41 at Craig-Hallum
01/21/21 Barclays
Nuance price target raised to $60 from $47 at Barclays
DSRLF DiaSorin SpA
$165.82 /

+0.8151 (+0.49%)

03/24/21 Berenberg
DiaSorin SpA price target lowered to EUR 150 from EUR 180 at Berenberg
03/18/21 Morgan Stanley
DiaSorin SpA downgraded to Underweight from Equal Weight at Morgan Stanley
12/10/20 Exane BNP Paribas
DiaSorin SpA price target raised to EUR 145 from EUR 135 at Exane BNP Paribas
12/10/20 Kepler Cheuvreux
DiaSorin SpA upgraded to Buy from Hold at Kepler Cheuvreux
LMNX Luminex
$32.92 /

+0.64 (+1.98%)

02/18/21 Piper Sandler
Luminex shares are undervalued, says Piper Sandler
12/17/20 BTIG
Illumina upgraded to Buy from Neutral at BTIG
11/09/20 Piper Sandler
Buy companies with COVID-19 tests on today's selloff, says Piper Sandler
11/06/20 Piper Sandler
Luminex's new product launches can drive long-term growth, says Piper Sandler
AFRM Affirm
$70.60 /

+0.81 (+1.16%)

03/25/21 BofA
Affirm initiated with a Neutral at BofA
03/17/21 Wedbush
LendingClub price target raised to $20.50 from $14 at Wedbush
03/17/21 Deutsche Bank
Affirm price target lowered to $92 from $120 at Deutsche Bank
02/16/21 Barclays
Affirm price target raised to $148 from $132 at Barclays
T AT&T
$30.04 /

+0.04 (+0.13%)

03/10/21 RBC Capital
Fortinet price target raised to $175 from $162 at RBC Capital
03/10/21 DA Davidson
Fortinet price target raised to $200 from $180 at DA Davidson
03/10/21 BTIG
Fortinet price target raised to $205 from $183 at BTIG
03/05/21 JPMorgan
JPMorgan sees AT&T rallying into analyst meeting, but not after
IIVI II-VI
$76.26 /

+0.04 (+0.05%)

03/30/21 Canaccord
II-VI price target lowered to $125 from $152 at Canaccord
03/26/21 Northland
NeoPhotonics deal 'makes more sense than ever' for Lumentum, says Northland
03/26/21 Cowen
II-VI weakness on deal announcement a buying opportunity, says Cowen
03/26/21 B. Riley
II-VI upgraded to Buy from Neutral at B. Riley Securities
GS Goldman Sachs
$330.85 /

-0.13 (-0.04%)

04/09/21 JMP Securities
Goldman Sachs price target raised to $400 from $338 at JMP Securities
04/08/21 Citi
Goldman Sachs price target raised to $390 from $370 at Citi
04/07/21 Barclays
Goldman Sachs price target raised to $420 from $392 at Barclays
04/01/21
Fly Intel: Top five analyst downgrades
CCL Carnival
$29.30 /

+0.73 (+2.56%)

04/09/21
Fly Intel: Top five analyst upgrades
04/09/21 Argus
Carnival upgraded to Buy from Hold at Argus sees 'strong' pent-up cruise demand
04/09/21 Argus
Carnival upgraded to Buy from Hold at Argus
04/09/21 Credit Suisse
Carnival upgraded to Outperform from Neutral at Credit Suisse
NCLH Norwegian Cruise Line
$30.53 /

-0.08 (-0.26%)

03/24/21 Stifel
Cruiseline stock selloff 'unwarranted,' says Stifel
03/18/21 UBS
Norwegian Cruise Line price target raised to $32 from $21 at UBS
03/16/21 JPMorgan
Norwegian Cruise Line price target raised to $36 from $33 at JPMorgan
03/12/21 Truist
Norwegian Cruise Line price target raised to $25 from $20 at Truist
RCL Royal Caribbean
$89.86 /

+0.08 (+0.09%)

03/18/21 UBS
Royal Caribbean price target raised to $116 from $79 at UBS
03/16/21 JPMorgan
Royal Caribbean price target raised to $110 from $100 at JPMorgan
03/12/21 Truist
Royal Caribbean price target raised to $68 from $48 at Truist
CS Credit Suisse
$10.64 /

-0.305 (-2.79%)

04/09/21
Fly Intel: Top five analyst downgrades
04/09/21 Morgan Stanley
Credit Suisse downgraded to Equal Weight from Overweight at Morgan Stanley
04/07/21 RBC Capital
Credit Suisse price target lowered to CHF 11 from CHF 14.50 at RBC Capital
04/07/21 Exane BNP Paribas
Credit Suisse downgraded to Neutral from Outperform at Exane BNP Paribas
T AT&T
$30.04 /

+0.04 (+0.13%)

RCL Royal Caribbean
$89.86 /

+0.08 (+0.09%)

NUAN Nuance
$45.59 /

+0.38 (+0.84%)

NCLH Norwegian Cruise Line
$30.53 /

-0.08 (-0.26%)

MSFT Microsoft
$255.73 /

+2.37 (+0.94%)

LMNX Luminex
$32.92 /

+0.64 (+1.98%)

IIVI II-VI
$76.26 /

+0.04 (+0.05%)

GS Goldman Sachs
$330.85 /

-0.13 (-0.04%)

CS Credit Suisse
$10.64 /

-0.305 (-2.79%)

CCL Carnival
$29.30 /

+0.73 (+2.56%)

AFRM Affirm
$70.60 /

+0.81 (+1.16%)

  • 05
    Mar
  • 01
    Mar
  • 23
    Feb
  • 13
    Jan
  • 18
    Nov
  • 14
    Oct
  • 17
    Jul
  • 02
    Jul
  • 06
    May
T AT&T
$30.04 /

+0.04 (+0.13%)

NCLH Norwegian Cruise Line
$30.53 /

-0.08 (-0.26%)

MSFT Microsoft
$255.73 /

+2.37 (+0.94%)

LMNX Luminex
$32.92 /

+0.64 (+1.98%)

IIVI II-VI
$76.26 /

+0.04 (+0.05%)

GS Goldman Sachs
$330.85 /

-0.13 (-0.04%)

DSRLF DiaSorin SpA
$165.82 /

+0.8151 (+0.49%)

CS Credit Suisse
$10.64 /

-0.305 (-2.79%)

CCL Carnival
$29.30 /

+0.73 (+2.56%)

AFRM Affirm
$70.60 /

+0.81 (+1.16%)

T AT&T
$30.04 /

+0.04 (+0.13%)

NUAN Nuance
$45.59 /

+0.38 (+0.84%)

NCLH Norwegian Cruise Line
$30.53 /

-0.08 (-0.26%)

MSFT Microsoft
$255.73 /

+2.37 (+0.94%)

LMNX Luminex
$32.92 /

+0.64 (+1.98%)

IIVI II-VI
$76.26 /

+0.04 (+0.05%)

GS Goldman Sachs
$330.85 /

-0.13 (-0.04%)

CS Credit Suisse
$10.64 /

-0.305 (-2.79%)

CCL Carnival
$29.30 /

+0.73 (+2.56%)

AFRM Affirm
$70.60 /

+0.81 (+1.16%)

T AT&T
$30.04 /

+0.04 (+0.13%)

RCL Royal Caribbean
$89.86 /

+0.08 (+0.09%)

NUAN Nuance
$45.59 /

+0.38 (+0.84%)

NCLH Norwegian Cruise Line
$30.53 /

-0.08 (-0.26%)

MSFT Microsoft
$255.73 /

+2.37 (+0.94%)

GS Goldman Sachs
$330.85 /

-0.13 (-0.04%)

CS Credit Suisse
$10.64 /

-0.305 (-2.79%)

CCL Carnival
$29.30 /

+0.73 (+2.56%)

AFRM Affirm
$70.60 /

+0.81 (+1.16%)

Periodicals
Harley-Davidson nominates Ford CEO to join board, Bloomberg reports » 19:47
04/11/21
04/11
19:47
04/11/21
19:47
HOG

Harley-Davidson

$42.06 /

+1.46 (+3.60%)

, F

Ford

$12.51 /

+0.005 (+0.04%)

Harley-Davidson (HOG)…

Harley-Davidson (HOG) nominated Ford Motor (F) Chief Executive Officer Jim Farley to join its board, the latest move by CEO Jochen Zeitz as he seeks to revive the struggling motorcycle maker and prepare it for an electric future, reported Bloomberg's Kristen Brown and Gabrielle Coppola. Reference Link

ShowHide Related Items >><<
HOG Harley-Davidson
$42.06 /

+1.46 (+3.60%)

F Ford
$12.51 /

+0.005 (+0.04%)

HOG Harley-Davidson
$42.06 /

+1.46 (+3.60%)

04/09/21
Fly Intel: Top five analyst upgrades
04/09/21 Northcoast
Harley-Davidson upgraded to Buy on 'robust' U.S. demand at Northcoast
04/09/21 Northcoast
Harley-Davidson upgraded to Buy from Neutral at Northcoast
03/31/21 Baird
Baird upgrades Harley-Davidson to Outperform as dealer survey improves
F Ford
$12.51 /

+0.005 (+0.04%)

04/05/21
Fly Intel: Top five analyst initiations
04/05/21 Wells Fargo
Ford initiated with an Overweight at Wells Fargo
03/29/21 Jefferies
Ford price target raised to $16 from $14 at Jefferies
03/19/21
Fly Intel: Top five analyst upgrades
HOG Harley-Davidson
$42.06 /

+1.46 (+3.60%)

F Ford
$12.51 /

+0.005 (+0.04%)

HOG Harley-Davidson
$42.06 /

+1.46 (+3.60%)

F Ford
$12.51 /

+0.005 (+0.04%)

HOG Harley-Davidson
$42.06 /

+1.46 (+3.60%)

F Ford
$12.51 /

+0.005 (+0.04%)

HOG Harley-Davidson
$42.06 /

+1.46 (+3.60%)

F Ford
$12.51 /

+0.005 (+0.04%)

Periodicals
Google 'Project Bernanke' revealed in Texas antitrust case, WSJ reports » 19:36
04/11/21
04/11
19:36
04/11/21
19:36
GOOG

Alphabet

$2,285.38 /

+20.38 (+0.90%)

, GOOGL

Alphabet Class A

$2,270.31 /

+20.25 (+0.90%)

Google for years operated…

Google for years operated a secret program that used data from past bids in the company's digital advertising exchange to allegedly give its own ad-buying system an advantage over competitors, report The Wall Street Journal's Jeff Horwitz and Keach Hagey, citing court documents filed in a Texas antitrust lawsuit. The program, known as "Project Bernanke," wasn't disclosed to publishers who sold ads through Google's ad-buying systems, note the authors. It generated hundreds of millions of dollars in revenue for the company annually, the documents show. In its lawsuit, Texas alleges that the project gave Google an unfair competitive advantage over rivals, adds the publication. Reference Link

ShowHide Related Items >><<
GOOGL Alphabet Class A
$2,270.31 /

+20.25 (+0.90%)

GOOG Alphabet
$2,285.38 /

+20.38 (+0.90%)

GOOG Alphabet
$2,285.38 /

+20.38 (+0.90%)

04/05/21 Evercore ISI
Alphabet assumed with an Outperform at Evercore ISI
04/01/21 Morgan Stanley
Microsoft making progress toward being 'Netflix of Gaming,' says Morgan Stanley
03/31/21 Wolfe Research
Alphabet initiated with an Outperform at Wolfe Research
03/30/21
Fly Intel: Top five analyst upgrades
GOOGL Alphabet Class A
$2,270.31 /

+20.25 (+0.90%)

04/09/21 Argus
Alphabet price target raised to $2,500 from $2,400 at Argus
GOOGL Alphabet Class A
$2,270.31 /

+20.25 (+0.90%)

GOOG Alphabet
$2,285.38 /

+20.38 (+0.90%)

GOOG Alphabet
$2,285.38 /

+20.38 (+0.90%)

GOOG Alphabet
$2,285.38 /

+20.38 (+0.90%)

GOOGL Alphabet Class A
$2,270.31 /

+20.25 (+0.90%)

GOOG Alphabet
$2,285.38 /

+20.38 (+0.90%)

Periodicals
Supply-chain software provider Blue Yonder weighing IPO, WSJ reports » 19:33
04/11/21
04/11
19:33
04/11/21
19:33
SAP

SAP

$133.79 /

+0.63 (+0.47%)

, ORCL

Oracle

$75.58 /

+0.29 (+0.39%)

Blue Yonder is planning…

Blue Yonder is planning to go public, the latest technology provider to look at a public stock offering as pandemic-driven upheaval in supply chains draws more interest to tools that help companies manage the flow of goods, reported The Wall Street Journal's Jennifer Smith. Blue Yonder said it has confidentially filed paperwork with the Securities and Exchange Commission for a proposed initial public offering, notes the author, adding that data research group Garner ranked Blue Yonder last year as the world's third-largest provider in the supply-chain-management software market, based on 2019 revenue, behind SAP SE (SAP) and Oracle (ORCL). Reference Link

ShowHide Related Items >><<
SAP SAP
$133.79 /

+0.63 (+0.47%)

ORCL Oracle
$75.58 /

+0.29 (+0.39%)

SAP SAP
$133.79 /

+0.63 (+0.47%)

04/09/21 Societe Generale
SAP price target lowered to EUR 136 from EUR 138 at Societe Generale
03/25/21 Credit Suisse
SAP assumed with an Outperform at Credit Suisse
03/12/21 JMP Securities
Domo price target raised to $89 from $80 at JMP Securities
03/10/21 Craig-Hallum
Talend go-shop 'could spark interest,' says Craig-Hallum
ORCL Oracle
$75.58 /

+0.29 (+0.39%)

04/09/21 Argus
Alphabet price target raised to $2,500 from $2,400 at Argus
04/07/21 UBS
Database checks not showing growth acceleration for Oracle, says UBS
03/31/21 Wedbush
Oracle reinstated with a Neutral at Wedbush
03/23/21 KeyBanc
Box price target raised to $27 from $22 at KeyBanc
SAP SAP
$133.79 /

+0.63 (+0.47%)

ORCL Oracle
$75.58 /

+0.29 (+0.39%)

SAP SAP
$133.79 /

+0.63 (+0.47%)

ORCL Oracle
$75.58 /

+0.29 (+0.39%)

SAP SAP
$133.79 /

+0.63 (+0.47%)

ORCL Oracle
$75.58 /

+0.29 (+0.39%)

SAP SAP
$133.79 /

+0.63 (+0.47%)

ORCL Oracle
$75.58 /

+0.29 (+0.39%)

Periodicals
Ingersoll-Rand nearing $1.7B deal to sell golf cart business, Reuters reports » 19:29
04/11/21
04/11
19:29
04/11/21
19:29
IR

Ingersoll-Rand

$50.59 /

+0.255 (+0.51%)

Ingersoll-Rand is nearing…

Ingersoll-Rand is nearing a deal to sell its golf cart business to Platinum Equity for around $1.7B, Reuters' Joshua Franklin, citing people familiar with the matter. The deal will separate Ingersoll Rand from a business it acquired in 1995 and is the latest in a series of divestitures that CEO Vicente Reynal has embarked on to pay down debt and streamline the company's portfolio, notes the author. Reference Link

ShowHide Related Items >><<
IR Ingersoll-Rand
$50.59 /

+0.255 (+0.51%)

IR Ingersoll-Rand
$50.59 /

+0.255 (+0.51%)

04/06/21 Barclays
Ingersoll-Rand price target raised to $56 from $53 at Barclays
02/24/21 Deutsche Bank
Ingersoll-Rand price target raised to $50 from $47 at Deutsche Bank
02/16/21 UBS
Ingersoll-Rand's deal to sell HPS interest 'positive,' says UBS
01/15/21 Jefferies
Ingersoll-Rand price target raised to $53 from $45 at Jefferies
IR Ingersoll-Rand
$50.59 /

+0.255 (+0.51%)

  • 17
    Jun
Periodicals
Apple agrees to testify before Senate on app store concerns, Reuters reports » 19:26
04/11/21
04/11
19:26
04/11/21
19:26
AAPL

Apple

$133.00 /

+2.63 (+2.02%)

A senior Apple executive…

A senior Apple executive has agreed to testify before the Senate on competition issues related to mobile app stores, reported Reuters' Paresh Dave. The company said in a letter sent to senators, seen by Reuters, that Chief Compliance Officer Kyle Andeer will be available to testify at an April 21 hearing held by part of the Senate Judiciary Committee. Reference Link

ShowHide Related Items >><<
AAPL Apple
$133.00 /

+2.63 (+2.02%)

AAPL Apple
$133.00 /

+2.63 (+2.02%)

04/09/21 Citi
Citi tells investors to focus on Apple's capital deployment, iPhone gains
04/08/21 Piper Sandler
Teen iPhone ownership continues to increase, says Piper Sandler
04/06/21 Cowen
Apple's News product a key growth pillar, says Cowen
04/06/21 Morgan Stanley
Morgan Stanley raises Services forecast for Apple, trims price target to $156
AAPL Apple
$133.00 /

+2.63 (+2.02%)

AAPL Apple
$133.00 /

+2.63 (+2.02%)

AAPL Apple
$133.00 /

+2.63 (+2.02%)

AAPL Apple
$133.00 /

+2.63 (+2.02%)

On The Fly
Box Office Battle: 'Godzilla vs. Kong' wins weekend with $13.4M » 19:22
04/11/21
04/11
19:22
04/11/21
19:22
T

AT&T

$30.04 /

+0.04 (+0.13%)

, CMCSA

Comcast

$53.55 /

-0.79 (-1.45%)

, CMCSK

Comcast

$58.00 /

+ (+0.00%)

, SNE

Sony

/

+

, LGF.A

Lionsgate

$16.12 /

+0.055 (+0.34%)

, LGF.B

Lionsgate

$13.82 /

+0.15 (+1.10%)

, DIS

Disney

$187.81 /

+0.485 (+0.26%)

, VIACA

ViacomCBS

$46.95 /

+0.48 (+1.03%)

, VIAC

ViacomCBS

$41.85 /

-0.43 (-1.02%)

"Box Office Battle" is…

ShowHide Related Items >><<
VIACA ViacomCBS
$46.95 /

+0.48 (+1.03%)

VIAC ViacomCBS
$41.85 /

-0.43 (-1.02%)

T AT&T
$30.04 /

+0.04 (+0.13%)

SNE Sony
/

+

LGF.B Lionsgate
$13.82 /

+0.15 (+1.10%)

LGF.A Lionsgate
$16.12 /

+0.055 (+0.34%)

DIS Disney
$187.81 /

+0.485 (+0.26%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$53.55 /

-0.79 (-1.45%)

T AT&T
$30.04 /

+0.04 (+0.13%)

03/10/21 RBC Capital
Fortinet price target raised to $175 from $162 at RBC Capital
03/10/21 DA Davidson
Fortinet price target raised to $200 from $180 at DA Davidson
03/10/21 BTIG
Fortinet price target raised to $205 from $183 at BTIG
03/05/21 JPMorgan
JPMorgan sees AT&T rallying into analyst meeting, but not after
CMCSA Comcast
$53.55 /

-0.79 (-1.45%)

04/09/21 Citi
Comcast price target raised to $62 from $59 at Citi
03/23/21 Macquarie
Disney 'realtive winner' from NFL rights deals, says Macquarie
03/18/21 Credit Suisse
Comcast price target raised to $67 from $61 at Credit Suisse
03/16/21 Wells Fargo
Wells starts Comcast at sell, says not good stock in current form
CMCSK Comcast
$58.00 /

+ (+0.00%)

02/23/21 Credit Suisse
SeaWorld price target raised to $52 from $34 at Credit Suisse
10/07/20 Benchmark
Benchmark would be 'aggressive buyer' of Comcast amid broader market weakness
09/22/20 Benchmark
Comcast price target raised to $60 from $54 at Benchmark
09/16/20 Pivotal Research
Comcast price target raised to $60 from $52 at Pivotal Research
SNE Sony
/

+

04/09/21 Benchmark
Netflix deal for Sony films 'hardly transformative,' says Benchmark
03/08/21 Macquarie
Sony downgraded to Neutral from Outperform at Macquarie
03/08/21 BofA
BofA says buy AMD and Nvidia as Steam data points to GPU upgrade tailwinds
01/12/21 Citi
Sony PS5 sales to date 'steady but somewhat disappointing,' says Citi
LGF.A Lionsgate
$16.12 /

+0.055 (+0.34%)

02/08/21 Deutsche Bank
Lionsgate price target raised to $16 from $12 at Deutsche Bank
02/05/21 RBC Capital
Lionsgate price target raised to $13 from $7 at RBC Capital
01/28/21 Macquarie
Lionsgate price target raised to $18 from $12 at Macquarie
LGF.B Lionsgate
$13.82 /

+0.15 (+1.10%)

11/02/20 Morgan Stanley
Lionsgate assumed with an Equal Weight at Morgan Stanley
09/02/20 Barrington
Lionsgate price target raised to $14 from $10 at Barrington
05/05/20 Canaccord
Lionsgate price target lowered to $13 from $16 at Canaccord
DIS Disney
$187.81 /

+0.485 (+0.26%)

04/08/21 KeyBanc
Netflix, Disney superior retention reinforces scale advantages, says KeyBanc
03/29/21 Loop Capital
ViacomCBS upgraded to Hold at Loop Capital after share price decline
03/24/21 B. Riley
Disney 'day-and-date' decision negative for exhibitors, says B. Riley
VIACA ViacomCBS
$46.95 /

+0.48 (+1.03%)

01/05/21 Gabelli
ViacomCBS named a best idea for 2021 at Gabelli
07/13/20
Fly Intel: Top five analyst initiations
07/13/20
Fly Intel: Top five analyst downgrades
VIAC ViacomCBS
$41.85 /

-0.43 (-1.02%)

04/07/21 Wolfe Research
Wolfe upgrades ViacomCBS to Outperform, sees 58% share upside
04/07/21 Wolfe Research
ViacomCBS upgraded to Outperform from Peer Perform at Wolfe Research
03/30/21
Fly Intel: Top five analyst upgrades
03/30/21 Gabelli
ViacomCBS upgraded to Buy from Hold at Gabelli
VIACA ViacomCBS
$46.95 /

+0.48 (+1.03%)

VIAC ViacomCBS
$41.85 /

-0.43 (-1.02%)

T AT&T
$30.04 /

+0.04 (+0.13%)

SNE Sony
/

+

LGF.A Lionsgate
$16.12 /

+0.055 (+0.34%)

DIS Disney
$187.81 /

+0.485 (+0.26%)

CMCSA Comcast
$53.55 /

-0.79 (-1.45%)

  • 06
    Apr
  • 29
    Mar
  • 24
    Mar
VIACA ViacomCBS
$46.95 /

+0.48 (+1.03%)

VIAC ViacomCBS
$41.85 /

-0.43 (-1.02%)

T AT&T
$30.04 /

+0.04 (+0.13%)

SNE Sony
/

+

LGF.A Lionsgate
$16.12 /

+0.055 (+0.34%)

DIS Disney
$187.81 /

+0.485 (+0.26%)

CMCSK Comcast
$58.00 /

+ (+0.00%)

CMCSA Comcast
$53.55 /

-0.79 (-1.45%)

VIACA ViacomCBS
$46.95 /

+0.48 (+1.03%)

T AT&T
$30.04 /

+0.04 (+0.13%)

SNE Sony
/

+

LGF.A Lionsgate
$16.12 /

+0.055 (+0.34%)

CMCSA Comcast
$53.55 /

-0.79 (-1.45%)

VIAC ViacomCBS
$41.85 /

-0.43 (-1.02%)

T AT&T
$30.04 /

+0.04 (+0.13%)

SNE Sony
/

+

DIS Disney
$187.81 /

+0.485 (+0.26%)

CMCSA Comcast
$53.55 /

-0.79 (-1.45%)

Recommendations
Volaris price target raised to $20.10 from $13 at Goldman Sachs » 19:13
04/11/21
04/11
19:13
04/11/21
19:13
VLRS

Volaris

$15.72 /

+0.125 (+0.80%)

Goldman Sachs analyst…

Goldman Sachs analyst Bruno Amorim raised the firm's price target on Volaris to $20.10 from $13 and keeps a Buy rating on the shares. The analyst expects Volaris to continue to outperform its competitors "on the recovery." He expects Volaris' consolidated capacity in 2021 to be above 2019 levels as a result of weakened competition in Mexico and the company's expansion strategy to new routes "filling the gap left by competitors."

ShowHide Related Items >><<
VLRS Volaris
$15.72 /

+0.125 (+0.80%)

VLRS Volaris
$15.72 /

+0.125 (+0.80%)

03/05/21 Citi
Volaris price target raised to $18.25 from $15.75 at Citi
02/22/21 Barclays
Volaris price target raised to $18 from $14 at Barclays
02/22/21 Deutsche Bank
Volaris upgraded to Buy from Hold at Deutsche Bank
02/16/21 Citi
Volaris price target raised to $15.75 from $13.25 at Citi
VLRS Volaris
$15.72 /

+0.125 (+0.80%)

  • 09
    Dec
Recommendations
OMA price target lowered to $49 from $50 at Goldman Sachs » 19:11
04/11/21
04/11
19:11
04/11/21
19:11
OMAB

OMA

$53.34 /

+0.46 (+0.87%)

Goldman Sachs analyst…

Goldman Sachs analyst Bruno Amorim lowered the firm's price target on OMA to $49 from $50 and keeps a Neutral rating on the shares. The analyst views the shares as fairly priced at current levels.

ShowHide Related Items >><<
OMAB OMA
$53.34 /

+0.46 (+0.87%)

OMAB OMA
$53.34 /

+0.46 (+0.87%)

03/24/21 BBVA
OMA downgraded to Market Perform from Outperform at BBVA
03/11/21 UBS
OMA downgraded to Neutral from Buy at UBS
12/14/20 Citi
OMA downgraded to Neutral from Buy at Citi
11/25/20 JPMorgan
OMA assumed at Overweight from Neutral at JPMorgan
Recommendations
Gol Linhas price target lowered to $9.85 from $11.05 at Goldman Sachs » 19:10
04/11/21
04/11
19:10
04/11/21
19:10
GOL

Gol Linhas

$8.28 /

-0.12 (-1.43%)

Goldman Sachs analyst…

Goldman Sachs analyst Bruno Amorim lowered the firm's price target on Gol Linhas to $9.85 from $11.05 and keeps a Buy rating on the shares following the stock's underperformance. Gol appears to have enough liquidity to cover its short-term debt, which could also be at least partially rolled over, Amorim tells investors in a research more. Moreover, if necessary, the capital markets conditions remain favorable, and Gol could seek additional funds to bolster its cash position, says the analyst.

ShowHide Related Items >><<
GOL Gol Linhas
$8.28 /

-0.12 (-1.43%)

GOL Gol Linhas
$8.28 /

-0.12 (-1.43%)

04/01/21 Itau BBA
Gol Linhas initiated with a Market Perform at Itau BBA
03/23/21 Morgan Stanley
Gol Linhas downgraded to Underweight from Equal Weight at Morgan Stanley
03/05/21 Deutsche Bank
Gol Linhas upgraded to Buy after recent selloff at Deutsche Bank
03/05/21 Deutsche Bank
Gol Linhas upgraded to Buy from Hold at Deutsche Bank
GOL Gol Linhas
$8.28 /

-0.12 (-1.43%)

GOL Gol Linhas
$8.28 /

-0.12 (-1.43%)

Downgrade
GAP Airports downgraded to Neutral from Buy at Goldman Sachs » 19:08
04/11/21
04/11
19:08
04/11/21
19:08
PAC

GAP Airports

$109.66 /

+0.105 (+0.10%)

Goldman Sachs analyst…

Goldman Sachs analyst Bruno Amorim downgraded GAP Airports to Neutral from Buy with a price target of $106, down from $120. The analyst sees a slower than previously expected recovery in traffic in the domestic market in Mexico and weaker traffic in Jamaican Airports. As such, he views the valuation as "tight" at current share levels.

ShowHide Related Items >><<
PAC GAP Airports
$109.66 /

+0.105 (+0.10%)

PAC GAP Airports
$109.66 /

+0.105 (+0.10%)

03/24/21 BBVA
GAP Airports downgraded to Market Perform from Outperform at BBVA
03/11/21 UBS
GAP Airports downgraded to Sell from Neutral at UBS
02/01/21 Citi
GAP Airports price target lowered to $116 from $122 at Citi
12/23/20 Citi
Airline demand in early 2021 'looks soft,' says Citi
PAC GAP Airports
$109.66 /

+0.105 (+0.10%)

Hot Stocks
DiaSorin SpA to acquire Luminex for $37 per share » 19:06
04/11/21
04/11
19:06
04/11/21
19:06
LMNX

Luminex

$32.92 /

+0.64 (+1.98%)

, DSRLF

DiaSorin SpA

$165.82 /

+0.8151 (+0.49%)

DiaSorin SpA (DSRLF)…

DiaSorin SpA (DSRLF) announced that its Board of Directors has unanimously approved and signed a definitive merger agreement for DiaSorin to acquire Luminex (LMNX) for a price of $37 per share in an all-cash transaction. This corresponds to a total equity value of approximately $1.8B on a fully diluted basis and an enterprise value of approximately $1.8B. Following the acquisition, the combined entity will have combined 2020 revenues of approximately EUR 1.25B, adjusted EBITDA of approximately EUR 472M, and positive Net Financial Position of approximately EUR 335M. The transaction is expected to close within the third quarter of 2021 and is subject to Luminex shareholder approval and to other customary closing conditions, including the satisfaction of antitrust and CFIUS regulatory requirements. The transaction will be immediately accretive to DiaSorin's earnings per share following closing of the transaction and will generate an attractive return on invested capital profile. The combination is also anticipated to result in cost synergies of approximately $55M within 3 years after closing.

ShowHide Related Items >><<
LMNX Luminex
$32.92 /

+0.64 (+1.98%)

LMNX Luminex
$32.92 /

+0.64 (+1.98%)

02/18/21 Piper Sandler
Luminex shares are undervalued, says Piper Sandler
12/17/20 BTIG
Illumina upgraded to Buy from Neutral at BTIG
11/09/20 Piper Sandler
Buy companies with COVID-19 tests on today's selloff, says Piper Sandler
11/06/20 Piper Sandler
Luminex's new product launches can drive long-term growth, says Piper Sandler
DSRLF DiaSorin SpA
$165.82 /

+0.8151 (+0.49%)

03/24/21 Berenberg
DiaSorin SpA price target lowered to EUR 150 from EUR 180 at Berenberg
03/18/21 Morgan Stanley
DiaSorin SpA downgraded to Underweight from Equal Weight at Morgan Stanley
12/10/20 Exane BNP Paribas
DiaSorin SpA price target raised to EUR 145 from EUR 135 at Exane BNP Paribas
12/10/20 Kepler Cheuvreux
DiaSorin SpA upgraded to Buy from Hold at Kepler Cheuvreux
LMNX Luminex
$32.92 /

+0.64 (+1.98%)

LMNX Luminex
$32.92 /

+0.64 (+1.98%)

LMNX Luminex
$32.92 /

+0.64 (+1.98%)

Upgrade
Copa Holdings upgraded to Buy from Neutral at Goldman Sachs » 19:04
04/11/21
04/11
19:04
04/11/21
19:04
CPA

Copa Holdings

$80.56 /

-0.68 (-0.84%)

Goldman Sachs analyst…

Goldman Sachs analyst Bruno Amorim upgraded Copa Holdings to Buy from Neutral with a price target of $100, up from $73. Copa company remains a "high-quality name" in Latin America Transportation with a "strong" balance sheet and strategic positioning due to its hub-based model with limited competition, Amorim tells investors in a research note. Further, the company's main competitors in Latin America are all undergoing restructuring processes, the analyst adds. Moreover, as the vaccination roll-out advances in Latin America and international demand recovers, Copa's 2023 EBITDA should be only 3% below 2019 levels, says Amorim.

ShowHide Related Items >><<
CPA Copa Holdings
$80.56 /

-0.68 (-0.84%)

CPA Copa Holdings
$80.56 /

-0.68 (-0.84%)

03/22/21 JPMorgan
Copa downgraded to Underweight on cautious sector view at JPMorgan
03/22/21 JPMorgan
Copa Holdings downgraded to Underweight from Neutral at JPMorgan
03/05/21 Wolfe Research
Wolfe upgrades Airlines sector to neutral on 'powerful market forces'
01/28/21 Deutsche Bank
Copa downgraded to Hold on slowing recovery at Deutsche Bank
CPA Copa Holdings
$80.56 /

-0.68 (-0.84%)

CPA Copa Holdings
$80.56 /

-0.68 (-0.84%)

Downgrade
Azul downgraded to Neutral from Buy at Goldman Sachs » 19:02
04/11/21
04/11
19:02
04/11/21
19:02
AZUL

Azul

$20.82 /

-0.86 (-3.97%)

Goldman Sachs analyst…

Goldman Sachs analyst Bruno Amorim downgraded Azul to Neutral from Buy with a price target of $22.20, up from $21.60. The analyst cites valuation for the downgrade. The shares are fully pricing in a "steep recovery" in demand for upcoming years, Amorim tells investors in a research note.

ShowHide Related Items >><<
AZUL Azul
$20.82 /

-0.86 (-3.97%)

AZUL Azul
$20.82 /

-0.86 (-3.97%)

03/23/21 Morgan Stanley
Azul downgraded to Underweight from Equal Weight at Morgan Stanley
03/22/21 JPMorgan
Azul downgraded to Underweight on cautious sector view at JPMorgan
03/22/21 JPMorgan
Azul downgraded to Underweight from Neutral at JPMorgan
03/05/21 Deutsche Bank
Azul upgraded to Buy after recent selloff at Deutsche Bank
Downgrade
Asur downgraded to Sell from Neutral at Goldman Sachs » 19:00
04/11/21
04/11
19:00
04/11/21
19:00
ASR

Asur

$183.91 /

-3.26 (-1.74%)

Goldman Sachs analyst…

Goldman Sachs analyst Bruno Amorim downgraded Asur to Sell from Neutral with a price target of $165, up from $135. Within the Mexican airports space, Asur's share price has recovered the most versus pre-pandemic levels, Amorim tells investors in a research note. The analyst views the current valuation as expensive and says that under a scenario of traffic downturn, the company would be less protected versus peers.

ShowHide Related Items >><<
ASR Asur
$183.91 /

-3.26 (-1.74%)

ASR Asur
$183.91 /

-3.26 (-1.74%)

03/24/21 BBVA
Asur upgraded to Outperform from Underperform at BBVA
03/11/21 UBS
Asur downgraded to Neutral from Buy at UBS
12/23/20 Citi
Airline demand in early 2021 'looks soft,' says Citi
12/04/20 Scotiabank
Asur downgraded to Underperform from Sector Perform at Scotiabank
ASR Asur
$183.91 /

-3.26 (-1.74%)

Periodicals
Microsoft in talks to buy Nuance for about $56 per share, Bloomberg says » 18:43
04/11/21
04/11
18:43
04/11/21
18:43
NUAN

Nuance

$45.59 /

+0.38 (+0.84%)

, MSFT

Microsoft

$255.73 /

+2.37 (+0.94%)

Microsoft (MSFT) is in…

Microsoft (MSFT) is in advanced talks to buy Nuance Communications (NUAN) in a deal with an equity value of about $16B, or about $56 per share, according to Bloomberg's Liana Baker, Kiel Porter, and Dina Bass, citing people familiar with the matter. Microsoft and Nuance have collaborated since 2019, noted the report, which added that an agreement could be announced as soon as this week. Nuance shares closed trading Friday, April 9, at $45.58 per share. Reference Link

ShowHide Related Items >><<
NUAN Nuance
$45.59 /

+0.38 (+0.84%)

MSFT Microsoft
$255.73 /

+2.37 (+0.94%)

NUAN Nuance
$45.59 /

+0.38 (+0.84%)

03/10/21 Wedbush
Nuance added to Best Ideas List at Wedbush
03/08/21 Morgan Stanley
Software industry rating raised to Attractive from In-Line at Morgan Stanley
02/09/21 Craig-Hallum
Nuance price target raised to $58 from $41 at Craig-Hallum
01/21/21 Barclays
Nuance price target raised to $60 from $47 at Barclays
MSFT Microsoft
$255.73 /

+2.37 (+0.94%)

04/09/21 BTIG
Okta upgraded to Buy from Neutral at BTIG
04/08/21 Morgan Stanley
CIO survey provides strong data points for Microsoft, says Morgan Stanley
04/05/21
Fly Intel: Top five analyst initiations
04/05/21 Credit Suisse
Microsoft assumed with an Outperform at Credit Suisse
NUAN Nuance
$45.59 /

+0.38 (+0.84%)

MSFT Microsoft
$255.73 /

+2.37 (+0.94%)

MSFT Microsoft
$255.73 /

+2.37 (+0.94%)

NUAN Nuance
$45.59 /

+0.38 (+0.84%)

MSFT Microsoft
$255.73 /

+2.37 (+0.94%)

NUAN Nuance
$45.59 /

+0.38 (+0.84%)

MSFT Microsoft
$255.73 /

+2.37 (+0.94%)

Hot Stocks
Checkmate presents new clinical trial translational data with Vidutolimod » 18:24
04/11/21
04/11
18:24
04/11/21
18:24
CMPI

Checkmate Pharmaceuticals

$10.52 /

+0.14 (+1.35%)

Checkmate Pharmaceuticals…

Checkmate Pharmaceuticals announced the presentation of new translational data from Checkmate's Phase 1b trial of vidutolimod in combination with pembrolizumab in patients with advanced anti-PD-1 refractory melanoma. Key highlights from these clinical data include: 93% of patients had progressive disease as their last response assessment on prior PD-1 blockade therapy, 42% had an elevated LDH, and the median sum of the target lesions longest diameter was 6.7 cm, indicating advanced disease; Response rates to vidutolimod in combination with pembrolizumab were similar across baseline patient characteristics including BRAF mutation, LDH level, number of prior systemic cancer treatments, best response to prior PD-1 blockade therapy, and prior ipilimumab; Responders and non-responders were not distinguished by baseline tumor characteristics including PD-L1 CPS, IFNg transcriptional signature, CD8+ T cells, or nonsynonymous mutations; All patients showed the expected rapid induction of anti-Qb antibodies to the virus-like particle, which facilitate the pharmacodynamic response to vidutolimod, and the antibody titers were not associated with clinical response; Clinical activity of vidutolimod in combination with pembrolizumab was associated with serum CXCL10 induction magnitude, induction of an inflammatory gene expression profile, and CD8+ T cells in injected and noninjected tumors.

ShowHide Related Items >><<
CMPI Checkmate Pharmaceuticals
$10.52 /

+0.14 (+1.35%)

CMPI Checkmate Pharmaceuticals
$10.52 /

+0.14 (+1.35%)

03/19/21 Jefferies
Checkmate Pharmaceuticals price target lowered to $19 from $23 at Jefferies
09/01/20 Jefferies
Checkmate Pharmaceuticals initiated with a Buy at Jefferies
09/01/20 BofA
BofA starts Checkmate Pharmaceuticals at Neutral ahead of more 'de-risking'
09/01/20 BofA
Checkmate Pharmaceuticals initiated with a Neutral at BofA
CMPI Checkmate Pharmaceuticals
$10.52 /

+0.14 (+1.35%)

  • 07
    Aug
Hot Stocks
BeiGene presents clinical data on Sitravatinib, Tislelizumab combo » 18:22
04/11/21
04/11
18:22
04/11/21
18:22
BGNE

BeiGene

$308.27 /

-5.8 (-1.85%)

, MRTX

Mirati Therapeutics

$170.25 /

+3.12 (+1.87%)

BeiGene (BGNE) announced…

BeiGene (BGNE) announced that clinical data on its anti-PD-1 antibody tislelizumab, in combination with the investigational spectrum-selective kinase inhibitor sitravatinib being jointly developed with Mirati Therapeutics (MRTX), were presented in two oral presentations at the American Association for Cancer Research Annual Meeting 2021. Data presented at the meeting were from two cohorts of a Phase 1b trial, in patients with unresectable or metastatic melanoma who were refractory or resistant to PD-1/L1 inhibitors and in patients with advanced platinum-resistant ovarian cancer. BeiGene has an exclusive collaboration and license agreement with Mirati for the development, manufacturing and commercialization of sitravatinib in Asia - excluding Japan, Australia, and New Zealand. This open-label, multicohort, Phase 1b trial was designed to evaluate safety/tolerability and preliminary antitumor activity of sitravatinib in combination with tislelizumab in advanced solid tumors. The primary endpoint of the trial was safety/tolerability of the combination; key secondary endpoints include investigator-assessed objective response rate, disease control rate, and progression-free survival per RECIST v1.1; overall survival was also assessed. At the time of data cutoff on October 13, 2020, a total of 25 patients with unresectable or metastatic melanoma who were refractory or resistant to anti-PD-1/L1 antibodies and had not received other prior immunotherapy had been enrolled in cohort G of the Phase 1b trial, including 12 with cutaneous subtype, seven with acral subtype, and four with mucosal subtype. At the time of data cutoff, 16 patients remained on study treatment. With a median follow-up time of 5.5 months, results included: All 25 patients experienced at least one treatment-emergent adverse event of any grade; Twelve patients experienced at least one Grade greater than or equal to 3 TEAE; One patient experienced a serious TEAE of anal abscess, associated with sitravatinib; Treatment discontinuation due to TEAEs occurred in two patients, with one discontinuing tislelizumab due to vaginal hemorrhage and the other sitravatinib due to increased BCK; Dose interruptions and reductions of sitravatinib occurred in 18 patients and 13 patients, respectively; All 25 patients were evaluable for efficacy and the confirmed ORR was 24%, including six partial responses, and the disease control rate was 88%; and the media duration of response was not reached, and the investigator-assessed median PFS was 6.7 months. Results in Patients with Advanced PROC include: At the time of data cutoff on October 13, 2020, a total of 60 patients with recurrent PROC who had no prior exposure to anti-PD-1/L1 antibodies had been enrolled in cohort E of the Phase 1b trial and 13 of them remained on study treatment. These patients received a median of four prior regimens. With a median follow-up time of six months, results included: Fifty-eight patients experienced at least one TEAE of any grade; Forty-one patients experienced at least one Grade greater than or equal to 3 TEAE; Forty-two patients experienced at least one serious TEAE; Treatment discontinuation due to TEAEs occurred in 23 patients, with nine patients discontinuing tislelizumab and 14 sitravatinib; Dose interruptions and reductions of sitravatinib occurred in 50 patients and 30 patients, respectively, and dose interruption of tislelizumab occurred in one patient; Four fatal TEAEs were reported, with none considered related to study treatment; Among the 53 patients who were evaluable for efficacy, the confirmed ORR was 26%; The median DoR was 4.7 months; and The median PFS and OS was 4.1 months and 12.9 months, respectively.

ShowHide Related Items >><<
MRTX Mirati Therapeutics
$170.25 /

+3.12 (+1.87%)

BGNE BeiGene
$308.27 /

-5.8 (-1.85%)

BGNE BeiGene
$308.27 /

-5.8 (-1.85%)

03/16/21 HSBC
BeiGene price target raised to $385 from $296 at HSBC
03/08/21 China Renaissance
BeiGene initiated with a Buy at China Renaissance
03/04/21 Goldman Sachs
Five Prime acquisition 'a strategic positive' for Amgen, says Goldman Sachs
03/01/21
Fly Intel: Top five analyst downgrades
MRTX Mirati Therapeutics
$170.25 /

+3.12 (+1.87%)

03/01/21 Oppenheimer
Mirati Therapeutics price target lowered to $255 from $260 at Oppenheimer
01/15/21 H.C. Wainwright
Mirati Therapeutics price target lowered to $257 from $265 at H.C. Wainwright
12/08/20 JMP Securities
Mirati Therapeutics initiated with a Market Perform at JMP Securities
11/17/20 BofA
Mirati Therapeutics downgraded to Underperform from Neutral at BofA
MRTX Mirati Therapeutics
$170.25 /

+3.12 (+1.87%)

BGNE BeiGene
$308.27 /

-5.8 (-1.85%)

  • 02
    Dec
  • 28
    Oct
MRTX Mirati Therapeutics
$170.25 /

+3.12 (+1.87%)

Hot Stocks
Lyra Therapeutics presents full data set from LANTERN Phase 2 study » 18:14
04/11/21
04/11
18:14
04/11/21
18:14
LYRA

Lyra Therapeutics

$11.15 /

-0.15 (-1.33%)

Lyra Therapeutics…

Lyra Therapeutics presented data from its Phase 2 LANTERN study of LYR-210, the company's lead long-acting product candidate for chronic rhinosinusitis, at the Combined Otolaryngology Spring Meetings 2021. LYR-210 is an investigational product candidate designed to be administered in-office and to deliver a sustained release therapeutic for up to six months at difficult-to-access nasal inflammation sites, as a non-invasive alternative to surgery for patients who have failed medical management. Lyra reported positive topline data from the LANTERN study in December 2020. The COSM oral presentation, titled Long-acting implantable corticosteroid matrix for chronic rhinosinusitis: Results of LANTERN Phase 2 randomized controlled study, contains the full 24-week data set from the company's Phase 2 clinical trial of LYR-210. Previously unpublished data included: improvement from baseline in bilateral ethmoid Zinreich scores by magnetic resonance imaging; symptom improvement in both polyp and non-polyp patients; and the need for and use of rescue medication during the trial. In Polyp vs Non-Polyp patients, symptom improvement was observed in both polyp and non-polyp patients, with 100% of patients at the 7500microgram dose in each group achieving the minimal clinically important difference of 8.9 points for SNOT-22 total score by week 24, with a single administration of LYR-210. In the LANTERN study, subjects underwent paranasal sinus MRI at baseline as well as at the end of treatment. LYR-210 achieved improvement in bilateral ethmoid Zinreich scores at week 24 in a dose-dependent manner, providing evidence of disease modification, with the 7500microgram dose achieving significant improvement compared to control between the two timepoints. Only 1 patient in the 7500microgram group and 2 patients in the 2500microgram group required a rescue treatment compared to 7 patients in the control group over the 24-week treatment period. The first incidence of rescue treatment in the control group occurred at week 2, while the only patient to require rescue treatment in the 7500microgram group did not require rescue treatment until after week 18. As such, LYR-210 reduced the need for rescue treatment. The need for rescue treatment in the LANTERN study was determined by the treating physician. Separately, Lyra has shared an analysis of the LANTERN study focused on a composite of three of the cardinal symptoms of CRS. Lyra announced an analysis of a composite score of three cardinal symptoms of CRS, which includes nasal blockage, nasal discharge and facial pain, which are the most prevalent symptoms for surgically naive CRS patients both with and without nasal polyps. With a single administration, LYR-210 achieved statistically significant improvement in the 3CS composite score compared to control at week 24 and at earlier timepoints.

ShowHide Related Items >><<
LYRA Lyra Therapeutics
$11.15 /

-0.15 (-1.33%)

LYRA Lyra Therapeutics
$11.15 /

-0.15 (-1.33%)

12/07/20 BofA
Lyra Therapeutics price target raised to $26 from $19 at BofA
05/26/20 BTIG
Lyra Therapeutics initiated with a Buy at BTIG
05/26/20 Jefferies
Jefferies starts Lyra Therapeutics at Buy with $24 price target
05/26/20 BofA
BofA starts Lyra Therapeutics at Buy with $21 price target
LYRA Lyra Therapeutics
$11.15 /

-0.15 (-1.33%)

  • 01
    May
LYRA Lyra Therapeutics
$11.15 /

-0.15 (-1.33%)

Hot Stocks
Blueprint presents data from registrational PATHFINDER trial of AYVAKIT » 18:09
04/11/21
04/11
18:09
04/11/21
18:09
BPMC

Blueprint Medicines

$94.14 /

+0.25 (+0.27%)

Blueprint Medicines…

Blueprint Medicines announced that multiple presentations across the company's leading systemic mastocytosis program were reported at the virtual American Association for Cancer Research Annual Meeting 2021. The presentations focused on registrational PATHFINDER trial data of AYVAKIT in advanced SM, PIONEER Part 1 data highlighting the impact of AYVAKIT on skin manifestations of SM, and Phase 1 trial data for BLU-263, a next-generation KIT D816V inhibitor. Blueprint Medicines is developing AYVAKIT for advanced and non-advanced SM, and BLU-263 to further address the range of patient needs in non-advanced SM and other mast cell disorders. In a pre-specified interim analysis from the PATHFINDER trial, 32 patients who primarily received a starting dose of 200 mg once daily were evaluable for response, as of a data cutoff date of June 23, 2020. Combined with Phase 1 EXPLORER trial results, these data support Blueprint Medicines' marketing applications in advanced SM under review in the U.S. and Europe. Overall, 75 percent of patients had a confirmed response, which was defined as complete remission with full or partial recovery of peripheral blood counts, partial remission or clinical improvement. The median time to response was two months, and all responses were ongoing at a median follow-up of 10.4 months. The CRh rate was 19 percent, with a median time to CRh of 5.6 months. These results show that responses deepened over time at a rate consistent with the EXPLORER trial. The company said that AYVAKIT led to robust and durable benefits across a number of additional clinical activity measures. In new patient-reported outcomes data, AYVAKIT showed a statistically significant reduction in total symptom score after 40 weeks, as measured by the Advanced Systemic Mastocytosis Symptom Assessment Form. Treatment with AYVAKIT resulted in robust improvements in patient-reported quality of life, based on the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire. Across multiple measures of mast cell burden, AYVAKIT showed profound reductions in serum tryptase, bone marrow mast cells, KIT D816V allele burden and spleen volume. Consistent with previously disclosed data, AYVAKIT was generally well-tolerated in 62 patients enrolled in the PATHFINDER trial, and most adverse events were reported as Grade 1 or 2. The most common AEs were peripheral edema, periorbital edema, thrombocytopenia, anemia, neutropenia, diarrhea, nausea, vomiting and fatigue. Three patients discontinued AYVAKIT due to treatment-related AEs, and most patients have remained on treatment as of the data cutoff date. In non-advanced SM, skin symptoms frequently persist and can severely impact quality of life. To assess the effects of AYVAKIT on mast cell burden in skin lesions, skin biopsies were obtained at baseline and week 12 in Part 1 of the PIONEER trial. Immunohistochemistry tests were performed to determine the proportion of aberrant mast cells in skin tissue, based on expression of CD25, CD30 and other transmembrane receptors observed in SM. Skin lesional tissue at baseline had more CD30-positive than CD25-positive mast cells. Following 12 weeks of treatment, AYVAKIT significantly reduced the proportion of aberrant CD30-positive mast cells in skin lesions compared to placebo, as of a data cutoff date of December 4, 2020. These data expand on previously reported results showing the impact of AYVAKIT on skin manifestations of SM, and suggest that CD30 may be an important biomarker of aberrant mast cells in SM-related skin lesions. A placebo-controlled, Phase 1 trial evaluated the safety, tolerability and pharmacokinetics of BLU-263 in healthy volunteers. This AACR presentation reported on single ascending dose cohorts and multiple ascending dose cohorts, as of a data cutoff date of November 9, 2020. BLU-263 was well-tolerated across all doses studied, and all AEs were reported as Grade 1. Pharmacokinetic data showed dose-dependent increases in systemic exposure of BLU-263, with the half-life of BLU-263 supporting once-daily dosing. Based on these results, the company plans to evaluate BLU-263 at doses ranging from 25 to 100 mg once daily in Part 1 of the Phase 2/3 HARBOR trial in patients with non-advanced SM, which the company plans to initiate in mid-2021.

ShowHide Related Items >><<
BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

04/09/21 Piper Sandler
AACR abstracts a 'win' for iTeos Therapeutics, says Piper Sandler
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
03/30/21 Credit Suisse
Blueprint Medicines initiated with a Neutral at Credit Suisse
02/18/21 Barclays
Blueprint Medicines price target raised to $95 from $90 at Barclays
BPMC Blueprint Medicines
$94.14 /

+0.25 (+0.27%)

Hot Stocks
Eli Lilly presents new data on Retevmo in Advanced RET Fusion-Positive in GI » 18:05
04/11/21
04/11
18:05
04/11/21
18:05
LLY

Eli Lilly

$184.47 /

+1.87 (+1.02%)

Eli Lilly announced for…

Eli Lilly announced for the first time data from the Phase 1/2 LIBRETTO-001 trial showing treatment with Retevmo demonstrated encouraging antitumor activity and safety across RET fusion-positive advanced solid tumors beyond lung and thyroid cancers, including multiple treatment-refractory gastrointestinal malignancies. In the Phase 1/2 LIBRETTO-001 trial, 32 adult patients with 12 unique RET fusion-positive advanced cancer types were enrolled by the efficacy cutoff date of September 19, 2020. Cancer types treated included pancreatic, colon, breast, salivary, sarcoma, carcinoid, rectal neuroendocrine, small intestine, xanthogranuloma, ovarian, pulmonary carcinosarcoma, and unknown primary cancers. Among the 32 patients, 62.5 percent had gastrointestinal tumors. Across all 32 patients, the confirmed objective response rate was 47 percent. Confirmed responses were observed in nine unique RET fusion-positive advanced cancer types. The median duration of response was not reached, with median follow-up of 13 months. Responses were ongoing in 73 percent of responding patients.

ShowHide Related Items >><<
LLY Eli Lilly
$184.47 /

+1.87 (+1.02%)

LLY Eli Lilly
$184.47 /

+1.87 (+1.02%)

04/06/21 JPMorgan
JPMorgan survey 'broadly positive' on Eli Lilly Alzheimer's drug
03/24/21 BMO Capital
AbCellera price target lowered to $59 from $61 at BMO Capital
03/17/21 Mizuho
AbbVie's FDA request show Xeljanz concerns may bleed to Rinvoq, says Mizuho
03/16/21 Mizuho
Mizuho sees 'good reasons to be optimistic' on Lilly's donanemab
LLY Eli Lilly
$184.47 /

+1.87 (+1.02%)

LLY Eli Lilly
$184.47 /

+1.87 (+1.02%)

LLY Eli Lilly
$184.47 /

+1.87 (+1.02%)

LLY Eli Lilly
$184.47 /

+1.87 (+1.02%)

Hot Stocks
Alnylam presents late-breaking data from ongoing Phase 1 study of ALN-AGT » 18:02
04/11/21
04/11
18:02
04/11/21
18:02
ALNY

Alnylam

$137.93 /

-4.405 (-3.09%)

Alnylam Pharmaceuticals…

Alnylam Pharmaceuticals announced interim results from the ongoing Phase 1 study of ALN-AGT, a subcutaneous investigational RNAi therapeutic targeting liver-expressed angiotensinogen for the treatment of hypertension. ALN-AGT treatment was associated with dose-dependent knockdown of AGT and reductions in blood pressure with a durability that supports the potential for a once quarterly or biannual dosing regimen, and was found to be generally safe and well tolerated. Eighty-four patients with hypertension were randomized in this double-blind, placebo-controlled, single ascending dose study evaluating the safety, tolerability and preliminary pharmacokinetic and pharmacodynamic activity of ALN-AGT. Patients, who were either treatment naive or had discontinued other anti-hypertensive medications prior to study entry, enrolled in ascending dose cohorts of 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, 400 mg or 800 mg ALN-AGT. Patients treated with single doses of ALN-AGT at 100 mg or higher experienced durable reductions in serum AGT of more than 90 percent through 12 weeks. In the 800 mg dose cohort, all patients experienced reductions in serum AGT of 96 - 98 percent at Week 12. Concomitant reductions in BP were observed with AGT knockdown, with clinically meaningful mean reductions in 24-hour systolic blood pressure of greater than 10 mm Hg observed at Week 8 after single doses of 100 mg or higher. At 800 mg, mean reductions in 24-hour SBP of 17 mm Hg were observed at Week 8 and sustained through Week 12. All data are as of a February 25, 2021 cut-off date. Suboptimal BP control remains the most common attributable risk factor for cardiovascular disease and cerebrovascular disease, and a leading cause of chronic kidney disease progression. These durable pharmacologic effects of ALN-AGT may support tonic control of BP with once quarterly and potentially biannual dosing. Less frequent dosing than available with current treatment options may help achieve improved medication adherence, an important part of maintaining BP control. ALN-AGT was shown to be generally well tolerated with an acceptable safety profile that supports advancement into Phase 2 studies. Most adverse events were mild or moderate in severity and resolved without intervention, with the most common AE consisting of mild and transient injection site reactions in 5 out of 56 patients receiving ALN-AGT. There were no clinically significant elevations in serum alanine aminotransferase, serum creatinine or serum potassium, and no patient required intervention for hypotension. There were no treatment-related serious AEs, deaths or AEs leading to study withdrawal.

ShowHide Related Items >><<
ALNY Alnylam
$137.93 /

-4.405 (-3.09%)

ALNY Alnylam
$137.93 /

-4.405 (-3.09%)

02/22/21 Guggenheim
Alnylam downgraded to Neutral from Buy at Guggenheim
02/12/21
Fly Intel: Top five analyst downgrades
02/12/21 Barclays
Alnylam price target raised to $196 from $162 at Barclays
02/12/21 Citi
Alnylam downgraded to Neutral from Buy at Citi
ALNY Alnylam
$137.93 /

-4.405 (-3.09%)

ALNY Alnylam
$137.93 /

-4.405 (-3.09%)

Hot Stocks
Greenwich LifeSciences presents immune response Phase IIb Poster » 17:59
04/11/21
04/11
17:59
04/11/21
17:59
GLSI

Greenwich LifeSciences

$53.50 /

+4.21 (+8.54%)

Greenwich LifeSciences…

Greenwich LifeSciences presented a poster of the final 5 year GP2 Phase IIb clinical trial immune response data at the 2021 AACR Annual Meeting. Immune response is the primary mechanism of action for GP2 and is critical to developing dosing and booster treatment strategies that are designed to achieve and sustain peak immunity, as well as to prevent metastatic breast cancer recurrences. The company said that potent immune response data supports the previously reported clinical outcome of 0% metastatic breast cancer recurrences over 5 years of follow up, if a patient completes the Primary Immunization Series over the first 6 months of GP2 treatment. Statistically significant peak immunity was reached after 6 months of GP2 treatment as measured in both the Dimer Binding Assay and the DTH skin test. HER2 3+ population immune response was similar to the HER2 1-2+ population immune response, suggesting the potential to treat the HER2 1-2+ population with GP2 immunotherapy in combination with trastuzumab based products and other clinically active agents. Broad based immune response suggests that GP2 immunotherapy and Herceptin based products may also have the potential to treat other HER2 1-3+ expressing cancers.

ShowHide Related Items >><<
GLSI Greenwich LifeSciences
$53.50 /

+4.21 (+8.54%)

  • 18
    Dec
  • 25
    Sep
GLSI Greenwich LifeSciences
$53.50 /

+4.21 (+8.54%)

GLSI Greenwich LifeSciences
$53.50 /

+4.21 (+8.54%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.